UK Pharma Challenges, DTC Ads Debate & 5 New FDA Approvals | Making Medicine

This week, John Stanford dives into the UK’s pharmaceutical challenges, including ABPI’s warning about declining competitiveness and major companies pausing investment. We also explore the debate over direct-to-consumer drug advertising in the U.S. and how it ties into investment decisions and the pill penalty. Finally, we close with August’s FDA approvals, celebrating breakthroughs for rare diseases and cancer patients.What do you think?Can the UK become Europe’s life sciences hub by 2030?Should the U.S. rethink DTC advertising, or does it play a vital role in innovation?Which of this month’s FDA approvals excites you most? If you're new to the Making Medicine Podcast, we're happy you're here! Follow us for more: https://x.com/MakingMedPodhttps://www.instagram.com/makingmedicinepod/ https://www.linkedin.com/showcase/making-medicine-podcast/about/?viewAsMember=true Timestamps: 0:00 Welcome to Making Medicine0:28 UK pharma outlook and ABPI report1:37 Weaknesses in UK drug investment2:24 Companies pausing UK investments3:08 U.S. vs UK drug access and pricing4:08 Global pressure for fair drug pricing4:33 MFN pricing concerns in the U.S.5:09 Debate over drug advertising6:09 How DTC ads affect biotech investment7:26 Connection to the pill penalty7:48 FDA Approvals Corner – August highlights8:17 Jazz Pharmaceuticals – Modeyso approval8:36 Boehringer Ingelheim – Hernexeos approval9:17 Other rare disease drug approvals10:23 Closing thoughts & FDA wins DISCLAIMER: We’re reporting on the headlines, not making medical recommendations. For personal health questions, always consult a doctor.